NonsparseOncologist (@5_utr) ranks #27 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 10 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: SERENA-6, MASTERPLAN, SANO. This profile quotes their 11 trial posts from 2026 word for word, with links to the originals on X.
At a Glance
- 11 posts naming a trial in 2026
- 8 trials discussed by name
- Lung Cancer: US #27 · 10 physicians engaged
This Month
What NonsparseOncologist has posted in the last 30 days. Updated November 10, 2026.
MASTERPLAN (Lancet Oncol, #ESMO26): randomized ph2, high-risk localized PDAC, chemo ± SBRT 40 Gy/5. 12-mo LRR 20.2% vs 52.0% (sHR 0.44). OS 22.0 vs 14.0 mo (HR 0.45). A large ΔLC with a survival signal, as the product predicts.
SANO at 5y: OS 50% vs 54%, but distant mets 46% vs 29% and 43% avoided surgery. There is no universal “best” of course, the Bayesian optimal action depends on patient covariates, their loss/utility weights. Preference-sensitive care, by design. #ESMO26 https://t.co/zvECsgdudv
NATALEE 6-year follow up is the best example of the mess that results in the Frequentist framework both in terms of multiplicity, and testing for any effect, even trivial 🧵 https://t.co/0Y587qAU0D
🔹 DASL-HiCaP (RT + ADT + darolutamide): MFS HR 0.42, 4-yr MFS 95% vs 88% 🔹 PROTEUS (surgery + ADT + apalutamide): MFS HR 0.80, 5-yr MFS 78.2% vs 73.5%
Who Amplifies NonsparseOncologist
Physicians who reposted NonsparseOncologist’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #27 | — | 10 | 11 | Full ranking |
Trials NonsparseOncologist Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| SERENA-6 | 5 | #21 of 39 | Apr 30, 2026 |
| MASTERPLAN | 1 | #9 of 11 | Oct 28, 2026 |
| SANO | 1 | #12 of 16 | Oct 25, 2026 |
| NATALEE | 1 | #24 of 46 | Oct 24, 2026 |
| DASL-HiCaP (ANZUP1801) | 1 | #25 of 28 | Oct 24, 2026 |
| PROTEUS | 1 | #49 of 56 | Oct 24, 2026 |
| MAVERICK (SWOG S1827) | 1 | #13 of 33 | Sep 13, 2026 |
| CROWN | 1 | #18 of 36 | May 30, 2026 |
NonsparseOncologist on SERENA-6
Fisher said consulting a statistician after the experiment is “like asking him to perform a post-mortem — he may be able to say what the experiment died of.” SERENA-6 died of p-hacking a biomarker clock. I’ll do the autopsy. 🧵 https://t.co/WuIZEDNNQG
SERENA-6 PFS2: a number between two other numbers, representing nothing, estimated from a singular information matrix, identifying a parameter in its own null space, published in @NEJM, submitted to the FDA as evidence of clinical benefit. Peer review works great. @f2harrell https://t.co/BEqpZCDLa6
First, the time origin. SERENA-6 starts the survival clock at ESR1m detection — a random stopping time driven by the same tumor biology predicting progression. Cox PH requires an exogenous origin. This one is endogenous by design. Violated before you run a line of code.
NonsparseOncologist on MASTERPLAN
MASTERPLAN (Lancet Oncol, #ESMO26): randomized ph2, high-risk localized PDAC, chemo ± SBRT 40 Gy/5. 12-mo LRR 20.2% vs 52.0% (sHR 0.44). OS 22.0 vs 14.0 mo (HR 0.45). A large ΔLC with a survival signal, as the product predicts.
NonsparseOncologist on SANO
SANO at 5y: OS 50% vs 54%, but distant mets 46% vs 29% and 43% avoided surgery. There is no universal “best” of course, the Bayesian optimal action depends on patient covariates, their loss/utility weights. Preference-sensitive care, by design. #ESMO26 https://t.co/zvECsgdudv
NonsparseOncologist on NATALEE
NATALEE 6-year follow up is the best example of the mess that results in the Frequentist framework both in terms of multiplicity, and testing for any effect, even trivial 🧵 https://t.co/0Y587qAU0D
NonsparseOncologist on DASL-HiCaP (ANZUP1801)
🔹 DASL-HiCaP (RT + ADT + darolutamide): MFS HR 0.42, 4-yr MFS 95% vs 88% 🔹 PROTEUS (surgery + ADT + apalutamide): MFS HR 0.80, 5-yr MFS 78.2% vs 73.5%
NonsparseOncologist on PROTEUS
🔹 DASL-HiCaP (RT + ADT + darolutamide): MFS HR 0.42, 4-yr MFS 95% vs 88% 🔹 PROTEUS (surgery + ADT + apalutamide): MFS HR 0.80, 5-yr MFS 78.2% vs 73.5%
NonsparseOncologist on MAVERICK (SWOG S1827)
MAVERICK: MRI surveillance +/- PCI for SCLC; SRS/WBRT if development of brain mets Primary endpoint, OS with a whopping NI margin of 25% greater hazard of death ❗️ and OS results premature https://t.co/lpKoASZHq8
NonsparseOncologist on CROWN
The precision oncology hype machine just found its new weapon to sell a paradigm. CROWN 7yr lorlatinib. 55% progression-free. Median PFS not reached. Proof the paradigm works. Except it isn’t. Let’s go. 🧵 https://t.co/sFm2JyM7wY
NonsparseOncologist’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Another precision oncology failure! Zombie 🧟 premise: that we can identify the causal driver, that it’s singular, that inhibiting it collapses the network. We can’t. It isn’t. It doesn’t. The oncogene is not the disease. It’s the mutation we happened to sequence. https://t.co/g0JNa4zkY6
92% DCR in pancreatic cancer. Extraordinary. Also meaningless. Here’s why DCR needs to die. 🧵 #AACR26 https://t.co/UukvhfmKkJ
🚨 Two major ARPI trials in high-risk localized prostate cancer, each adding a drug to standard local therapy 🧵 #ProstateCancer #RadOnc #pcsm https://t.co/bgjcc8ckZL
Holy smokes mOS 22 vs 14 months (p=0.006) @jryckman3 @TonyFelefly https://t.co/gty5hE4P3J
❗️ AREST pT1-2N0 SCC oral cavity SCC w/intermediate risk factor(s) -> adjuvant RT vs observation 3-year LRFS HR 0.52 (0.30-0.91) in favor of adjuvant RT Wow #ASCO26 https://t.co/qcLzOQGyJE